Similar Items: Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
- The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
- Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
- The production of murine monoclonal antibodies using in vitro immunization
- Technology advancements in antibody purification [Corrigendum]
- The use of monoclonal antibody for the immunodiagnosis of Fasciola gigantica infection in cattle
- Current GMP standards for the large‐scale production of monoclonal antibodies